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Abstract
Depression in men with prostate cancer is a significant and complex issue that can challenge clinicians’ diagnostic
efforts. The objective of the current study was to evaluate prototypic and male-specific depression symptoms and
suicidal ideation in men with a diagnosis of prostate cancer relative to those with and without comorbidity. The Patient
Health Questionnaire-9 (PHQ-9) and Male Depression Risk Scale-22 (MDRS-22) were completed online along with
demographic and background variables by 100 men with a diagnosis of prostate cancer (n = 54 prostatectomy, n =
33 receiving active treatment). Hierarchical logistic regression was used to examine recent (past 2 weeks) suicide
ideation. Over one-third of the sample (38%) reported a comorbidity, and this group had significantly higher total
depression scores on the PHQ-9 (Cohen’s d = 0.65), MDRS-22 emotion suppression (d = 0.35), and drug use subscales
(d = 0.38) compared to respondents without comorbidity. A total of 14% reported recent suicidal ideation, of which
71.4% of cases were identified by the PHQ-9 “moderate” cut-off, and 85.7% of cases were identified by the MDRS22 “elevated” cut-off. After control variables, MDRS-22 subscales accounted for 45.1% of variance in recent suicidal
ideation. While limited by the exclusive use of self-report data, findings point to the potential benefits of evaluating
male-specific symptoms as part of depression and suicide risk screening in men with prostate cancer and the need to
be mindful of the heightened risk for depression among men with prostate cancer who have comorbidity.
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The majority of men diagnosed with prostate cancer have
high 10-year survival rates due to improved screening,
detection, and treatments (Wong et al., 2016). Unfortunately,
these men have heightened risk for depression related to
unmet psychosocial needs, prostate cancer–related symptoms, and treatment side effects that can include sexual
dysfunction and urinary incontinence (Chambers et al.,
2017). Many men with prostate cancer can suffer from
additional health problems (i.e., sexual dysfunction and
heart disease) that may contribute to depressive symptoms
(D’Amico, Chen, Renshaw, Loffredo, & Kantoff, 2008;
Saini et al., 2013). Depression among men with prostate
cancer has emerged as a significant issue with prevalence
reported at 16% to 30% (Christie & Sharpley, 2014; Sharp,
O’Leary, Kinnear, Gavin, & Drummond, 2016; Sharpley,

Bitsika, & Christie, 2010, 2013; Sharpley & Christie,
2007). Depression in prostate cancer is associated with
men experiencing a loss of masculine identity (Sharpley,
Bitsika, & Denham, 2014). Severe depression is a known
risk for suicide, especially among older prostate cancer
patients (Llorente et al., 2005). Although awareness of
depression in prostate cancer has grown, the wider men’s
health literature suggests depression among men is underdiagnosed (Oliffe & Phillips, 2008). Research attention has
thus been increasingly devoted to the specificities of men’s
depressive symptoms, the contexts in which they are experienced, and the methods and tools used to formally evaluate depression in men.
The generic diagnostic criteria for major depressive
disorder, as per the Diagnostic and Statistical Manual
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(DSM-5), have been critiqued as gender neutral and
insufficient to comprehensively evaluate depression in
men (Sharpley, Bitsika, & Christie, 2014). At a broad
level, such critiques have produced a focus on highlighting male-specific depressive symptoms and the design
and testing of tools to more accurately diagnose and treat
men’s depression. Systematic reviews and population
studies support these efforts by arguing for the existence
of a subtype of depression in men characterized by alcohol/substance use and externalizing symptoms including
anger and irritability (Cavanagh, Wilson, Kavanagh, &
Caputi, 2017; Martin, Neighbors, & Griffith, 2013).
Expansion of the assessment of depression may be particularly important for men with prostate cancer. For
example, Sharp et al. (2016) argued that psychological
evaluation of men with prostate cancer should be
informed by better understanding their cancer-related
symptoms, rather than focusing on the major depressive
disorder criteria. This was based on findings that men
who experience prostate cancer–related urinary incontinence and those treated with androgen deprivation therapy, who in turn experienced fatigue and insomnia, were
more likely to be depressed (Sharp et al., 2016).
Unpleasant emotions and social withdrawal from others
were also highlighted as significant factors associated
with depression severity in a sample of 800 prostate cancer patients (Sharpley et al., 2010).
Nonetheless, depression scales that emphasize internalizing symptoms in the diagnosis of major depressive
disorder continue to be used widely in prostate cancer
patients. For example, the Patient Health Questionnaire-9
(PHQ-9) performed reliably in testing several aspects of
depression in cancer patients (Hinz et al., 2016); however, according to Sharpley et al. (Sharpley, Bitsika, &
Christie, 2014), the PHQ-9 does not fully capture the
dimensions of depression as they manifest in men with
prostate cancer. Specifically, the PHQ-9 and the Gotland
Male Depression Scale (GMDS) were compared for
their capacity to measure the prevalence of depression in

191 men with prostate cancer, and approximately 24% of
the men screened as depressed on the GMDS were not
identified by the PHQ-9 (Sharpley, Bitsika, & Christie,
2014). The GMDS has, however, drawn criticisms
regarding psychometric validity, highlighting the need
for measurement refinement amid the emergence of
other male depression scales (Rice, Aucote, MöllerLeimkühler, & Amminger, 2017). Among the newer
scales, the Male Depression Risk Scale-22 (MDRS-22)
has shown much promise and has been validated in general populations of Canadian and Australian men to identify males at risk of depression (Rice et al., 2017; Rice,
Oliffe, Kealy, & Ogrodniczuk, 2018). The scale assesses
six broad externalizing domains of depression symptoms
in men, including emotion suppression and anger and
aggression, and may offer improved detection and early
intervention among males at risk for depression and suicidal ideation.
The objective of the current study was to evaluate and
compare PHQ-9 and MDRS-22 self-report data among
men with prostate cancer relative to those with and without comorbidities (e.g., cardiovascular problems, arthritis, and chronic pain). The second aim was to evaluate the
predictive ability of the MDRS-22 in identifying recent
suicidal ideation in this population. Given evidence suggesting that men with prostate cancer who experience
comorbidity report greater psychosocial stress and poorer
outcomes (D’Amico et al., 2008; Saini et al., 2013), it
was predicted that higher scores for prototypic and malespecific depression symptoms would be observed among
men reporting comorbidity.

Methods
Participants
This study used a convenience sample of 100 Canadian
men with prostate cancer, recruited online and via social
media. Men self-identified as having prostate cancer and
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Table 1. Group Comparison for PHQ-9 Items.
Total sample,
N = 100

No comorbidity,
n = 62

Comorbidity,
n = 38

M (SD)

M (SD)

M (SD)

F

p

Cohen’s d

Little interest or pleasure in
doing things

0.72 (0.95)

0.60 (0.91)

0.92 (1.00)

2.48

.099

0.33

Feeling down, depressed, or
hopeless

0.68 (0.82)

0.52 (0.74)

0.94 (0.87)

7.00

.010

0.52

Trouble falling asleep or sleeping
too much

1.00 (1.03)

0.79 (0.91)

1.34 (1.15)

7.11

.009

0.53

Feeling tired or having little
energy

1.14 (1.09)

0.81 (0.97)

1.68 (1.07)

17.81

<.001

0.85

a

PHQ-9 item

Group comparison

Poor appetite or overeating

0.62 (0.87)

0.50 (0.82)

0.82 (0.92)

3.15

.079

0.36

Feeling bad about yourself or
that you are a failure or have
let yourself or family down

0.56 (0.70)

0.47 (0.67)

0.71 (0.73)

2.88

.093

0.34

Trouble concentrating on things,
such as reading the newspaper
or watching television

0.63 (0.87)

0.48 (.80)

0.86 (0.93)

4.75

.032

0.34

Moving or speaking so slowly
that other people could have
noticed. Or the opposite being
so fidgety or restless that you
have been moving around a lot
more than usual

0.30 (0.58)

0.19 (.44)

0.47 (0.72)

5.81

.018

0.47

Thoughts that you would be
better off dead or of hurting
yourself in some way

0.20 (0.55)

0.16 (.45)

0.26 (0.55)

0.81

.372

0.20

Note. aPHQ-9 item scores range 0–3. PHQ-9 = Patient Health Questionnaire-9; SD = standard deviation.

indicating year of diagnosis and providing information
regarding current treatment and symptoms.

Measures
Demographic information included country and province
of residence, age, employment status, education level,
sexual identity, cultural affiliation, year diagnosed with
prostate cancer and year treated, prostate cancer
treatment[s], and current treatment. Data for comorbidity
were collected using an item labeled “Other health challenges” to which respondents could indicate “yes” [Please
specify] or “no.” The PHQ-9 (Kroenke, Spitzer, &
Williams, 2001), developed from the diagnostic criteria
for major depressive disorder, comprises nine items
reflecting the diagnostic criteria in the DSM-V (American
Psychological Association [APA], 2013). Respondents
indicated how often (0 = “not at all,” 1 = “several days,”
2 = “more than half the days,” and 3 = “nearly every
day”) they had been bothered by any of the listed
problems over the last 2 weeks (see Table 1 for items).
The PHQ-9 has excellent validity for individuals with

mild, moderate, and severe depression (Kroenke et al.,
2001), with aggregate scores ranging from 0 to 27 that
map minimal depression (0–4), mild depression (5–9),
moderate depression (10–14), moderately severe depression (15–19), and severe depression (20–27). The MDRS22 comprises 22 items and six subscales focused on
externalizing depression symptoms (Rice, Fallon, Aucote,
& Möller-Leimkühler, 2013). Respondents, thinking
back over the last month, responded to each item considering how often (0 = not at all to 7 = almost always) specific statements applied to them (see Table 2 for MDRS-22
subscales). The MDRS-22 exhibits test–retest stability
and excellent psychometric properties (Rice et al., 2015)
and has been validated in Australian and Canadian samples with the total score characterizing those in the low
(0–31), elevated (32–50), high (51–86), and extreme
ranges (87–154; Rice et al., 2017).

Procedure
Following approval from the behavioral ethics review
board at (University of British Columbia), the survey was
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Table 2. Group Comparison for MDRS-22 Subscales.
Total sample,
N = 100

No comorbidity,
n = 62

Comorbidity,
n=38

M (SD)

M (SD)

M (SD)

F

p

Cohen’s d

Emotion suppression

8.73 (7.73)

7.58 (6.96)

10.61 (8.61)

4.56

.035

0.38

Drug use

1.03 (3.24)

0.50 (1.87)

1.89 (4.58)

4.77

.031

0.38

a

MDRS-22 Subscale

Group comparison

Alcohol use

2.51 (4.97)

2.71 (5.35)

2.18 (4.32)

0.20

.656

0.11

Anger and aggression

3.53 (5.18)

2.91 (4.37)

4.53 (6.22)

2.71

.103

0.30

Somatic symptoms

5.14 (5.35)

4.56 (5.38)

6.08 (5.25)

1.22

.140

0.28

Risk-taking

1.30 (2.61)

1.37 (2.44)

1.18 (2.88)

0.04

.843

0.07

a

Note. MDRS-22 subscales range 0–28 for emotion suppression, alcohol use, anger and aggression, and somatic symptoms; MDRS-22 subscales
range 0–21 for the drug use and risk-taking subscales. MDRS = Male Depression Risk Scale-22; SD = standard deviation.

embedded in an online prostate cancer psychosocial
resource. The website and survey were launched in
January 2017, highlighting the issue of depression in men
with prostate cancer, and the opportunity for respondents
to be entered into a $500 cash prize draw by completing
the survey. The survey was available for 3 months to
April 2017, and recruitment was aided by targeted
Facebook ads and social media posts inviting men with
prostate cancer to respond by clicking on the hyperlinked survey. The survey landing page provided details
about the study including consent, confidentiality
regards respondent’s demographic data, and its separate
password protected storage from their survey responses,
along with details about the aggregated data being
shared as study findings in an academic publication and
presentations. On completion of the survey, respondents
were provided the URL of a men’s depression website
(https://headsupguys.org/), which provided visitors with
male-specific depression information and supports.

Data Analysis
Analyses were undertaken in SPSS 22.0 (IBM Corp.).
Descriptive statistics were used to characterize the sample based on self-reported sexuality, cultural affiliation,
and highest education. Independent sample t tests were
used to compare groups (i.e., those with and without selfreported comorbidity) on age, and χ2 analyses were used
to evaluate the associations between treatment groups
(i.e., current active treatment and watchful waiting),
recent diagnosis (i.e., last 12 months), and highest education level. Reliability for the PHQ-9 and MDRS-22 subscales was calculated using Cronbach’s α coefficients.
Multivariate analysis of covariance was conducted on the
PHQ-9 items and MDRS-22 subscales, controlling for current treatment and age. χ2 analysis evaluated established
PHQ-9 categories (i.e., normal PHQ-9 = 0–4, minimal

PHQ-9 = 5–9, mild PHQ-9 = 10–14, and moderate–
severe PHQ-9 = 15–27) according to those with and without comorbidities. Hierarchical logistic regression was
undertaken to predict recent (past 2 weeks) suicide ideation, as assessed by PHQ-9 item nine, controlling for
age, recent diagnosis, current treatment, and sexuality
(step 1) and comorbidity (step 2), with MDRS-22 subscales entered at step 3.

Results
Sample Characteristics
Mean age of the sample was 64.8 (standard deviation
[SD] = 7.18) years, ranging 47 to 85. The vast majority of
the sample identified as heterosexual (n=96), and four
participants identified as gay, bisexual, or preferred not to
say. Most (n = 87) participants identified as Caucasian.
More than 60% of the sample reported higher education:
some college/trade school (n = 19); graduation from college/trade school (n = 23); some university (n = 7); undergraduate degree (n = 17); and graduate degree (n = 21).
Of the 38 participants indicating a comorbidity in addition to their prostate cancer diagnosis, only one reported
a diagnosis of depression. A total of 11 participants
reported multimorbidities. The remaining cases reported
challenges with cardiovascular health (n = 10), arthritis
(n = 7), chronic pain (n = 2), or other (n = 8; gallstones,
diabetes). Recent suicidal ideation was relatively infrequent in the present sample (n = 14). One-third (n = 33)
of the sample were receiving active treatment, and just
over half (n=54) reported a prostatectomy.
There was no significant age difference between those
without comorbidity (M = 64.55 years, SD = 7.07) and
those reporting comorbidity (M = 65.24 years, SD = 7.42),
p = .644. There was no association between those
reporting comorbidity and current active treatment (n = 33,
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Figure 1. PHQ-9 and MDRS-22 categories (percentage with comorbidity).

χ2(1) = 0.40, p = .522), watchful waiting (n = 22,
χ2(1) = 1.72, p = .189), recent diagnosis of prostate cancer (i.e., last 12 months; n = 35, χ2(1) = 0.16, p = .690),
highest education level (χ2(6) = 8.56, p = .200), or recent
suicidal ideation (n = 6, χ2(1) = 0.16, p = .686).

Scale Reliability
The PHQ-9 demonstrated satisfactory internal consistency (Cronbach’s α = .89). For the MDRS-22, all subscales reported satisfactory internal consistency: emotion
suppression (α =.88), drug use (α =.91), alcohol use
(α =.91), anger and aggression (α =.92), somatic symptoms (α =.67), though internal consistency was low for
the risk-taking subscale (α =.59). A subsequent sensitivity analysis of the risk-taking subscale, however, identified that the risk-taking subscale was internally consistent
for those <65 years (n = 46, α =.70) relative to males ≥65
years (n = 54, α =.07).

Comparison of Symptom Profiles
For the PHQ-9 total score, those with comorbidity
reported significantly higher depression scores (M = 8.02,
SD = 5.56) compared to those without comorbidity
(M = 4.52, SD = 5.19), F(1, 96) = 10.87, p = .001, Cohen’s
d = 0.65. Neither current treatment (p = .738) or age
(p = .097) was significant covariates. When the nine
PHQ-9 symptoms were examined in a multivariate

analysis, a significant omnibus effect was observed, Λ =
0.811, F(9, 90) = 2.33, p = .021, partial η2 = .189. Current
treatment (p = .832) and age (p = .789) were not significant covariates. Significant univariate effects were
observed for five major depression symptoms; higher
scores were observed for those with comorbidity for low
mood, sleep disturbance, fatigue, concentration difficulty,
and psychomotor disturbance (see Table 1).
Categorical analysis was undertaken according to
PHQ-9 depression categories. A significant association
indicated that those with comorbidity were less likely to
be in the normal range and more likely to be in the mild
and moderate symptom ranges than those with no
comorbidity χ2(3, N = 100) = 8.024, p = .046. The same
association held for the MDRS-22 χ2(3, N = 100) = 8.30,
p = .040 (see Figure 1).
For the MDRS-22 total score, there was a nonsignificant trend for those with comorbidity to report higher
scores (M = 26.47, SD = 21.24) compared to those without
comorbidity (M = 19.65, SD = 17.64), F(1, 96) = 3.92,
p = .051, Cohen’s d = 0.35, with neither current treatment
(p = .931) or age (p = .097) significant as covariates. When
the MDRS-22 subscales were examined in a multivariate
analysis, a significant multivariate effect was observed,
Λ=.863, F(6, 91) = 2.41, p = .033, partial η2 = .132, with
neither current treatment (p = .992) or age (p = .058) significant covariates. At the univariate level, there was a
significant effect for the emotion suppression subscale,
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F(1, 96) = 4.56, p = .035, and the drug use subscale,
F(1, 96) = 4.77, p = .031. In both instances, scores were
higher among men with comorbidities.

Suicidal Ideation
Of the 14 respondents who endorsed suicidal ideation, the
PHQ-9 cut-off score for “moderate depression” identified
71.4% (n = 10) of those men, while the MDRS-22 “elevated” cut-off identified 85.7% (n = 12). Bivariate correlations were calculated between PHQ-9 total scores and
the MDRS-22 subscales. Significant correlations were
observed for five of the MDRS-22 subscales; emotion
suppression (r = .66, p < .001), drug use (r = .22, p =
.025), anger and aggression (r = .59, p < .001), somatic
symptoms (r = .46, p < .001), and risk-taking (r=.41, p <
.001). The logistic regression model was not significant
with the control variables entered at either step 1 (χ2(4) =
3.51, p =.447) or step 2 (χ2(5) = 3.77, p = .609) but was
significant when the six MDRS-22 subscales were simultaneously entered at step 3 (χ2(11) = 33.75, p < .001). The
model explained 51.8% of variance in recent suicide ideation, with the MDRS-22 subscales accounting for 45.1%
of variance (Nagelkerke R2). Increasing MDRS-22 emotion suppression subscale scores were a significant predictor (Wald = 5.78, odds ratio [OR] = 1.18, p = .016),
with a trend observed for the anger and aggression subscale (Wald = 3.80, OR = 1.19, p = .051).

Discussion
There was a consistent pattern of higher scores for major
depression symptoms for those men with prostate cancer
reporting comorbidities (i.e., cardiovascular disease and
arthritis), with a robust moderate effect size for the group
difference in PHQ-9 total scores. Those reporting comorbidities were more likely to be in the mild or moderate–
severe range on the PHQ-9 than those without other
health challenges. Specific effects were noted for low
mood, sleep disturbance, fatigue, concentration difficulty,
and psychomotor disturbance. This suggests that the likelihood of depression may increase in men experiencing
prostate cancer who have comorbidities. These results
indicate that it is not only the likelihood of depression
severity that increases but also that the expression of
depressive symptoms may be different for men with prostate cancer who also report comorbidity. Given that many
men with prostate cancer are in their sixth, seventh, and
eighth decades, this is an important consideration in routinely evaluating depression levels in men with prostate
cancer. It is likely that many of these men were treated
with polypharmacy agents, some of which in and of
themselves might heighten their risk for depression
(Higano, 2003). There was no significant difference
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between those with and without comorbidities with
regards to the suicidal ideation item on the PHQ-9. While
this may reflect an equivalent degree of suicidal ideation
between the two groups, there may also be benefit in
more fully evaluating suicidality in men with prostate
cancer beyond the single PHQ-9 item, “Thoughts that you
would be better off dead, or of hurting yourself in some
way.”
Patterns for the MDRS-22 were less consistent. Those
reporting additional health challenges had significantly
higher scores for the emotion suppression and drug use
subscales. The drug use effect might be explained by
respondents with comorbidity being reliant on polypharmacy agents for a range of conditions. In this regard, the
MDRS-22 likely yields diverse interpretations of the drug
use items wherein some respondents may use illicit drugs
recreationally, responding on that basis, while others such
as the current sample might be responding based on their
prescription drug use. Nonetheless, since men with
comorbidity were markedly more distressed (based on
PHQ-9 scores) than those without comorbidity, this difference remains cause for some concern—perhaps suggesting the overuse of drugs for emotional coping and/or
for management of a higher pain burden. The effect for
emotion suppression, which demonstrated the strongest
correlation with the PHQ-9, suggests that those with
comorbidity may attempt to self-censor and withhold the
expression of negative emotion. Such responses may
actually increase the likelihood of developing additional
physical and mental health problems (Hoyt, Stanton,
Irwin, & Thomas, 2013; Mauss & Gross, 2004).
Furthermore, the current study findings indicate that the
MDRS-22 risk-taking subscale may be less reliable in
older men (i.e., those ≥65 years). This may be somewhat
expected and likely reflects older men’s more conservative practices.
Beyond differences in symptom expression between
men with and without comorbidities, unique associations
were reported between overall depressive severity and two
male-specific domains of the MDRS-22. Based on the
regression analyses, anger and aggression also appeared to
be salient among men with prostate cancer and comorbidity, while emotion suppression appeared to be an important
factor associated with prototypic symptoms of depression
in men with prostate cancer in general. As older men,
respondents may have aligned to traditional masculine ideals around stoicism and relied on anger and aggression to
express their emotions, which in turn can manifest as maladaptive coping. Experiencing prostate cancer and comorbidity may further threaten one’s sense of self as a man,
evoking unmodulated anger (in protest and/or in compensation) for their compromised health. Results from the
regression analyses indicated that the MDRS-22 subscales
accounted for a large proportion of variance in the PHQ-9
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scores, approximately 48% for those without comorbidity
and 53% of variance for those with comorbidities. The current study findings suggest evaluation of emotion suppression in men with prostate cancer, along with anger and
aggression in men with prostate cancer and comorbidity as
important avenues of future research. That emotion suppression was identified to be a significant predictor of suicide ideation with a trend also observed for anger and
aggression, suggests that additional research attention is
paid to more fully apprehend and address these potential
connections.

Clinical Implications
The current study findings have implications for
researchers and care providers. Both groups should be
aware of comorbidities in men with prostate cancer as
depression risk factors, given this appears to be associated with higher PHQ-9 scores in the current sample.
Supporting this recommendation, depression also
appears to be underdiagnosed in this population. For
example, among those reporting comorbidity, only one
participant self-reported a diagnosis of depression.
Figure 1 shows that there were 13 cases (i.e., 34%) in the
comorbidity subgroup achieving the PHQ-9 cut-off score
for either mild or moderate–severe depression. The
observation that 22 of the 100 respondents’ PHQ-9
scores also indicated mild to moderate–severe depression supports estimates of prevalence in the literature
(Christie & Sharpley, 2014; Sharp et al., 2016; Sharpley
et al., 2010, 2013; Sharpley & Christie, 2007).
Furthermore, given their association with PHQ-9 scores,
emotion suppression and anger and aggression in men
should be taken into account by clinicians working with
men who experience prostate cancer. This finding supports work by Sharpley and Bitsika (2014) and others
(Oliffe & Phillips, 2008; Rice et al., 2013) indicating that
a range of male-specific symptoms exist beyond those
identified by generic depression screening tools, and that
nuanced differences in the expression of such symptoms
may emerge in the context of prostate cancer and comorbid conditions.
A proportion of men with prostate cancer will also
experience suicidal ideation. Emotion suppression was
found to be predictive of suicidal ideation in the present
sample. When assessing for depression in this population,
sensitive clinical enquiry regarding suicidal thoughts is
suggested, along with assessing the likelihood of emotion
suppression, given the potential association between
these two constructs. Taking a wider view, adopting brief
general screening tools such as the Distress Thermometer,
a single-item measure validated in populations of men
experiencing prostate cancer (Chambers, Zajdlewicz,
Youlden, Holland, & Dunn, 2014), may also assist as a
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way to introduce clinical conversations about suicidal
thinking.
In terms of prevention and treatment of depressive
symptoms, Sharpley, Bitsika, Wootten, and Christie (2014)
advocated for peer supports as an effective way to
increase men’s resilience for coping with prostate cancer
and alleviating depressive symptoms. A systematic
review of randomized controlled trials drawn from programs to improve the psychological well-being of men
with prostate cancer highlighted 11 effective interventions (Chambers et al., 2017). These included online psychoeducation and moderated peer forums; however,
these interventions and their evaluations were not based
on translational knowledge about masculinity and malespecific symptoms of depression (Chambers et al., 2017).
Cormie et al. (2016) asserted the need to appeal to men’s
masculine values through group-based physical exercise
interventions. Such approaches may to promote social
connectedness and reduce depression among men with
prostate cancer (Cormie, Galvão, et al., 2015; Cormie,
Turner, Kaczmarek, Drake, & Chambers, 2015). Building
on these insights and recommendations by Sharpley
et al. (2017), future work might also focus on prevention
and treatments of depression among specific subgroups,
with formal evaluation of prostate cancer psychosocial
programs inclusive of end-users’ depressive symptoms
and scores over time.
More broadly, findings have implications for the
field of men’s depression research. In the present sample, the MDRS-22 cut-off identified additional cases of
suicidality that fell below the PHQ-9 cut-off. As suggested by others (Rice, Kealy, Oliffe, & Ogrodniczuk,
2018), case identification may be improved by supplementing the use of standard depression symptom rating
scales with male-specific measures. Furthermore, emotion suppression predicted suicidality in the present
sample. This accords with recent population-based epidemiological work indicating that men’s stoicism is a
robust predictor of suicidal ideation (Pirkis, Spittal,
Keogh, Mousaferiadis, & Currier, 2017). Ongoing attention to men’s use of emotion suppression and tendency
for stoicism is indicated.

Study Limitations
The current study has several limitations: the use of
nonprobability sampling precludes generalizability of
ﬁndings; the cross-sectional design prohibits causal
inference; the exclusive use of self-report measures
including the lack of follow-up screening and diagnosis
by a clinician; and the small sample size. Furthermore,
suicidal ideation was assessed by a single item from the
PHQ-9; however, research has previously supported use
of this item (Walker et al., 2010). Future studies should
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use large samples and longitudinal designs to fully
examine the role of age, comorbidities, and treatment
modalities in men’s depression across the prostate cancer trajectory.

Summary
To address depression in men with prostate cancer, more
effective screening for depressive symptoms is needed,
and future interventions should be designed and formally
evaluated on understandings of relative depression risk
and specific symptomatology in men with prostate cancer. By highlighting the increased risk for depression in
men with prostate cancer who have comorbidity, and the
predictive nature of emotion suppression and anger and
aggression on PHQ-9 scores, the current study reveals
the need for asking additional clinical and research questions of this subgroup of men who are vulnerable to
depression.
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